A NEW DIRECTION in Treating Alzheimer's Disease and Parkinson's Disease and Other Neurodegenerative Conditions 

Our Treatments

​

We are developing novel treatments for Alzheimer’s Disease (AD), Parkinson’s (PD) and other neurodegenerative diseases. Our lead candidate, ANVS401, simultaneously inhibits the production of multiple neurotoxic brain proteins that have been shown to impair axonal transport and lead to nerve cell death. Specifically, it inhibits the synthesis of amyloid precursor protein (APP), Tau and α-Synuclein.  It is distinct from other AD drugs in development, because, unlike many other drugs that attempt to remove one toxic protein, ANVS401 inhibits the toxic proteins before they can form, and it inhibits all the major neurotoxic proteins responsible for AD and PD.

EXECUTIVES AND ADVISORS

MARIA L. MACCECCHINI, Ph. D.
Founder, President, CEO and Executive Board Member 
 

Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.

JEFFREY MCGROARTY 

Chief Financial Officer
 

Mr. McGroarty is a financial executive with experience in investor relations, working with analysts, creditors and financial institutions, planning and analysis, capital allocation, SEC communications and reporting, accounting, acquisitions and turnarounds.  He is experienced in effectively managing complex projects, building professional relations and developing staff.  Mr. McGroarty was previously employed as CFO of Safeguard Scientifics, Interim Controller at Cephalon, Inc., Vice President-Financial Planning and Analysis of Exide Technologies, Inc., and Senior Manager at PWC. Jeff’s MBA is from the Wharton School of Business.

JEFFREY CUMMINGS, M.D.
Chef Medical Advisor and SAB Member
 

Dr. Cummings completed a Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, director of the Deane F. Johnson Center for Neurotherapeutics at UCLA and director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Cleveland, and Florida. He is a past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited 30 books and published nearly 600 peer-reviewed papers.

WILLIAM MOBLEY, Ph.D.

Chief Scientific Advisor and SAB Member
 

Dr. Mobley is a distinguished Professor, Department of Neurosciences, Florence Riford Chair for Alzheimer Research and Associate Dean for Neurosciences Initiatives at UC San Diego. He is a member of the National Academy of Medicine. His research focuses on the neurobiology of neurotrophic factor actions/signaling and on the hypothesis that dysfunction of such signaling mechanisms contributes to neuronal dysfunction in developmental and age-related disorders of the neurosystem.

SCIENTIFIC ADVISORY BOARD

SIDNEY STRICKLAND, Ph. D.
SAB Chairman
 

Dr. Strickland is Vice President and Dean for Educational Affairs and Research Professor, Patricia and John Rosenwald Laboratory of Neurobiology and Genetics at Rockefeller University. Dr. Strickland’s laboratory investigates how dysfunction of the circulatory system contributes to Alzheimer’s and other neurodegenerative disorders.  He will serve as the Chairman of Annovis Bio’s SAB.

WILLIAM MOBLEY, Ph. D.
Chief Scientific Advisor and SAB Member
 

Dr. Moblley is a distinguished professor, Department of Neurosciences, Florence Riford Chair for Alzheimer Research and Associate Dean for Neurosciences Initiatives, at UC San Diego and SAB Member. He is a member of the National Academy of Medicine. His research focuses on the neurobiology of neurotrophic factor actions/signaling and on the hypothesis that dysfunction of such signaling mechanisms contributes to neuronal dysfunction in developmental and age-related disorders of the neurosystem.

JEFFREY CUMMINGS, M.D.
Chief Medical Advisor and SAB Member
 

Dr. Cummings completed a neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and Director of the Cleveland Clinic Lou Ruvo Center.

GREGORY PETSKO, Ph. D.
SAB Member
 

Dr. Petsko is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. His research interests are directed towards understanding the biochemical bases of neurological diseases like Alzheimer’s, Parkinson’s, and ALS discovering treatments (especially by using structure-based drug design), that could therapeutically affect those biochemical targets, and seeing any resulting drug candidates tested in humans. He has also made key contributions to the field of protein crystallography.  

MICHAEL B. HOFFMAN
Chairman of  the Board
 

Mr. Hoffman is the Founder and Managing Partner of Stone Capital Partners, a private equity firm focused on power and renewable energy. He was Partner of Riverstone, senior managing director at the Blackstone Group and managing director at Smith Barney, Harris Upham & Co. He serves as Chairman of Annovis Bio, Onconova, Curative and is on the Board of Rockefeller University.

MARK WHITE 
Board Member 
 

Mr. White is a biopharmaceutical executive with global marketing, business development and sales experience.  Currently, Mark is an independent consultant and a member of Robin Hood Ventures, a Philadelphia based angel investor group. Previously, Mark held senior level roles at Pfizer in marketing and commercial development, where he led the successful global launches of Inspira, Revatio, Lyrica and Xeljanz. In his last position, he was Vice President Worldwide Marketing, with global responsibility for new product development and in-line marketing for Pfizer’s Inflammation Therapeutic Area.

CLAUDINE E. BRUCK, Ph. D.
Board Member
 

Dr. Bruck is a pharmaceutical executive and scientist with a strong entrepreneurial drive. Exhibited successes in building a therapeutic research unit de novo and leading discovery and clinical development of biological (vaccines, biopharmaceuticals) and small molecule medicines as well as an ophthalmic drug portfolio. With creativity and a strong results-focus, she is energized to challenge and lead teams. Extensive Pharmaceutical industry experience spans drug discovery and development across several therapeutic.

ROBERT M. WHELAN, JR.
Board Member
 

Mr. Whelan brings over 35 years of corporate finance and investment banking experience to Annovis’ Board of Directors. Since 2001, Mr. Whelan has been President of Whelan & Company, LLC, providing financial consulting, valuation and strategic services to public and private companies in the technology, healthcare and alternative energy industries. From 1999 to 2001, Mr. Whelan served as Vice Chairman, Prudential Volpe Technology Group. Prior to then, Mr. Whelan was a senior executive with Volpe Brown Whelan, a private technology and healthcare investment banking, brokerage and asset management firm.

MARIA L. MACCECCHINI, Ph. D.
Executive Board Member
 

Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Founder and CEO of Annovis (f.k.a. Symphony Pharmaceuticals)  focused on protecting brain cells after stroke. It sold in 2001 to Transgenomic.

Three Patented Families of Compounds